Skip to main content

Carotid Stenosis

7
Pipeline Programs
10
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
1
5
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 9 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
3 programs
3
CEA and TCD monitoringPhase 41 trial
MelatoninPhase 41 trial
MelatoninPhase 41 trial
Active Trials
NCT01210937Unknown150Est. Dec 2014
NCT03115034Completed60Est. Nov 2017
NCT03419767Unknown60Est. Jun 2018
Biocorp
BiocorpFrance - Issoire
1 program
1
ClopidogrelPhase 41 trial
Active Trials
NCT01572623Unknown150Est. Sep 2012
Boston Scientific
Boston ScientificCA - Valencia
1 program
1
NexStent Carotid Stent SystemPhase 41 trial
Active Trials
NCT00478673Terminated298Est. Jul 2009
Yuyu Pharma
Yuyu PharmaKorea - Seoul
1 program
1
Ticlopidine + Ginko bilobaPhase 31 trial
Active Trials
NCT02133989Unknown86Est. Dec 2017
Prevail Therapeutics
1 program
1
AbciximabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT00178451Withdrawn0
Elutia
ElutiaSILVER SPRING, MD
1 program
CorMatrix ECM for Carotid RepairN/A1 trial
Active Trials
NCT01569594Completed230Est. Dec 2016
Contego Medical
Contego MedicalNC - Raleigh
1 program
Neuroguard IEP Direct SystemN/A1 trial
Active Trials
NCT05845710Completed178Est. Aug 2025
Innovation Pharmaceuticals
1 program
carotid endarterectomyN/A1 trial
Active Trials
NCT03840265Unknown100Est. Nov 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
UNION therapeuticsMelatonin
UNION therapeuticsMelatonin
BiocorpClopidogrel
UNION therapeuticsCEA and TCD monitoring
Boston ScientificNexStent Carotid Stent System
Yuyu PharmaTiclopidine + Ginko biloba
Contego MedicalNeuroguard IEP Direct System
Innovation Pharmaceuticalscarotid endarterectomy
ElutiaCorMatrix ECM for Carotid Repair

Clinical Trials (10)

Total enrollment: 1,312 patients across 10 trials

NCT03419767UNION therapeuticsMelatonin

Insulin Resistance in Patients After Carotid Revascularization

Start: Aug 2017Est. completion: Jun 201860 patients
Phase 4Unknown
NCT03115034UNION therapeuticsMelatonin

Melatonin in Patients Under Carotid Endarterectomy

Start: Jun 2016Est. completion: Nov 201760 patients
Phase 4Completed
NCT01572623BiocorpClopidogrel

Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting

Start: Jul 2011Est. completion: Sep 2012150 patients
Phase 4Unknown
NCT01210937UNION therapeuticsCEA and TCD monitoring

Early Warning and Optimization Strategy in Carotid Endarterectomy

Start: Jan 2010Est. completion: Dec 2014150 patients
Phase 4Unknown
NCT00478673Boston ScientificNexStent Carotid Stent System

Post-Approval Study of the NexStent Carotid Stent System and the FilterWire EZ Embolic Protection System: SONOMA

Start: May 2007Est. completion: Jul 2009298 patients
Phase 4Terminated
NCT02133989Yuyu PharmaTiclopidine + Ginko biloba

Clopidogrel Resistance and Embolism in Carotid Artery Stenting

Start: Jun 2014Est. completion: Dec 201786 patients
Phase 3Unknown
NCT00178451Prevail TherapeuticsAbciximab

Stroke Prevention With Abciximab in Carotid Endarterectomy

0
Phase 1/2Withdrawn
NCT05845710Contego MedicalNeuroguard IEP Direct System

Direct Access Carotid Artery Stenting Using the Neuroguard IEP System (PERFORMANCE III)

Start: Oct 2023Est. completion: Aug 2025178 patients
N/ACompleted
NCT03840265Innovation Pharmaceuticalscarotid endarterectomy

Evaluation of Cerebrovascular Events in Patients With Occlusive Carotid Artery Disorders

Start: Feb 2019Est. completion: Nov 2022100 patients
N/AUnknown
NCT01569594ElutiaCorMatrix ECM for Carotid Repair

CorMatrix ECM for Carotid Repair Following Endarterectomy Registry

Start: Apr 2012Est. completion: Dec 2016230 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.